Is medicinal ketamine associated with urinary dysfunction issues? Assessment of both the European Medicines Agency (EMA) and the UK Yellow Card Scheme pharmacovigilance database-related reports

Nicolo Schifano, Stefania Chiappini, Fabio Castiglione, Andrea Salonia, Fabrizio Schifano

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)
53 Downloads (Pure)

Abstract

Objective: A range of ketamine-induced uropathy (KIU) issues have been typically described in ketamine misusers. Conversely, more knowledge is needed in terms of medicinal ketamine-related urological disturbances, since ketamine prescribing is being increasingly considered for a range of medical and psychopathological conditions. Methods: To assess medicinal KIU issues, we aimed at analyzing both the 2005–2017 European Medicines Agency (EMA) and the 2006–2018 UK Yellow Card Scheme (YCS) pharmacovigilance databases. Results: A total number (eg, all categories) of 11 632 EMA ketamine-related adverse drug reaction (ADR) reports were here identified. Out of these, some 9971 ADRs (eg, 85.7% of the total) were judged as “suspect” and were here analyzed. Some 1758 ADRs (17.7% of 9971, corresponding to 194 individual patients) referred to urological issues, relating to either kidney/ureter (922 ADRs) or bladder/urethra (837 ADRs). Ketamine was the sole drug administered in 156/194 (80.4%) cases/patients. Although most cases occurred in the 1 month-1 year time frame following the start of ketamine prescribing, in 30 cases the ADR occurred within 48 hours. Most ADR-related cases resolved, although both sequelae (18 cases) and fatalities (79/1758; 4.5%) were recorded. Overall, YCS data were consistent with EMA findings, with some 50/217 (23%) ADRs referring to renal/urinary disorders. Conclusions: Current data may only represent a gross underestimate of the KIU real prevalence issues. It is here suggested that chronic treatment involving higher doses/repeated exposure to ketamine be restricted to the context of controlled trials or clinical audits.

Original languageEnglish
Pages (from-to)230-237
JournalLUTS: Lower Urinary Tract Symptoms
Volume13
Issue number2
DOIs
Publication statusPublished - 9 Oct 2020

Keywords

  • LUTS
  • drug abuse
  • ketamine
  • ketamine uropathy
  • lower urinary tract dysfunction

Fingerprint

Dive into the research topics of 'Is medicinal ketamine associated with urinary dysfunction issues? Assessment of both the European Medicines Agency (EMA) and the UK Yellow Card Scheme pharmacovigilance database-related reports'. Together they form a unique fingerprint.

Cite this